A Phase I/II Trial of Hsp 90 Inhibitor AUY-922 in Patients With Lung Adenocarcinoma With "Acquired Resistance" to EGFR Tyrosine Kinase Inhibitors.

Trial Profile

A Phase I/II Trial of Hsp 90 Inhibitor AUY-922 in Patients With Lung Adenocarcinoma With "Acquired Resistance" to EGFR Tyrosine Kinase Inhibitors.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Jul 2016

At a glance

  • Drugs Luminespib (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 30 Jun 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 30 Jun 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 24 Jun 2015 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top